Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · MOREPENLAB

MOREPEN LAB.

HealthcarePharmaceuticals & Biotechnology₹5055 cr market cap
₹90.90 ▼ -1.59% today As of 19 Nov 2026
52-week low ₹33.6852-week high ₹146.97

-37.2% from the 52-week high · +174.3% above the low

Morepen Laboratories Ltd. engages in the manufacture and market of bulk drugs and pharmaceutical formulations. The company is headquartered in Gurgaon, Haryana and currently employs 1,649 full-time employees. The firm is engaged in the business of manufacturing, producing, developing, and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also the home health products. Its APIs include Apixaban, Edoxaban, Sitagliptin, Linagliptin, Empagliflozin, Atorvastatin, Loratadine, Desloratadine, Montelukast Sodium, Atorvastatin Calcium, Fexofenadine, Sitagliptin Phosphate, Vildagliptin and Rivaroxaban, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

The short version. MOREPEN LAB. reported revenue of ₹747 crore for Sep 2026, up 81.3% from a year earlier. Net profit was ₹89 crore (up 117.1% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 35.65% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

MOREPEN LAB. trades 37.2% below its 52-week high and 174.3% above its 52-week low.

Change over period: —

1M-24.0%
3M+4.5%
6M+117.2%
1Y+102.1%

2 · The business

Is it growing?

Sales, year on year+81.3%

Sep 2026 revenue of ₹747 cr.

Profit, year on year+117.1%

Sep 2026 net profit of ₹89 cr.

Net margin11.9%

2.0 pts higher than a year earlier.

3-year growth34.9% profit

Revenue compounded at 8.7% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue747570485484412425466453
Net profit8956162841112027
Net margin %11.99.93.25.79.92.54.45.9
EPS (₹)1.621.030.290.50.750.20.370.49

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue180618121690141815471188853769
Net profit951189639102973429
Net margin %5.36.55.72.76.68.23.93.8
EPS (₹)1.732.151.880.762.132.160.750.64

3 · The quality

How well does it turn capital into profit?

Return on equity was 7.6% in Mar 2026; debt to equity is 0.16.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %7.610.211.35.1
Return on capital %9.412.815.67.3
EBITDA margin %9.510.510.16.0
Net margin %5.26.55.62.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR8.7%8.8%
Profit CAGR34.9%-0.5%
Debt to equity0.16
Interest cover8.3x
Current ratio2.37
P/E ratio27.1

4 · The owners

Who holds it, and are they adding?

Promoter holding35.65%

Unchanged over 8 quarters.

Foreign institutions3.43%

Up 1.21 pts over 8 quarters.

Domestic institutions1.71%

Up 0.07 pts over 8 quarters.

Mutual fund schemes6

+3 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter35.6535.6535.6535.6535.6535.6535.6535.650.0
FII2.221.941.721.621.621.581.463.43+1.21
DII1.641.671.511.51.251.251.281.71+0.07
Public60.4760.7261.1161.2161.4661.561.5959.19-1.28

Mutual fund holdings · Oct 2026

6 schemes hold this stock

3 the month before.

  • UNION ACTIVE MOMENTUM FUND2.1% of NAV
  • Bandhan BSE Healthcare Index Fund0.25% of NAV
  • Motilal Oswal BSE Healthcare ETF0.24% of NAV
  • ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.03% of NAV
  • Motilal Oswal BSE 1000 Index Fund0.02% of NAV
  • ADITYA BIRLA SUN LIFE BSE TOTAL MARKET ETF0.02% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for MOREPEN LAB. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about MOREPEN LAB.

What is the MOREPEN LAB. share price?

MOREPEN LAB. (MOREPENLAB) last closed at ₹90.90, down 1.59% on the day. Its 52-week range is ₹33.68 to ₹146.97.

What is the market cap of MOREPEN LAB.?

MOREPEN LAB. has a market capitalisation of about ₹5,055 crore. Its price-to-earnings ratio is 27.1.

How are MOREPEN LAB.'s latest results?

MOREPEN LAB. reported revenue of ₹747 crore for Sep 2026, up 81.3% from a year earlier. Net profit was ₹89 crore (up 117.1% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 35.65% in Sep 2026, up 0.00 points over 8 quarters.

Who owns MOREPEN LAB.?

As of Sep 2026, shareholding was: Promoter 35.65%, FII 3.43%, DII 1.71%, Public 59.19%.

How many mutual funds hold MOREPEN LAB.?

6 mutual fund schemes held MOREPEN LAB. in October 2026. That compares with 3 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 29 Aug 2025 · Final Dividend - Rs. 0.2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.